KẾT QUẢ HOÁ XẠ TRỊ ĐỒNG THỜI PHÁC ĐỒ CISPLATIN-ETOPOSIDE SỬ DỤNG KĨ THUẬT XẠ ĐIỀU BIẾN LIỀU TRÊN BỆNH NHÂN UNG THƯ PHỔI TẾ BÀO NHỎ GIAI ĐOẠN KHU TRÚ TẠI BỆNH VIỆN K

Abstract

Objective: This study aimed to evaluate the efficacy and safety of concurrent chemoradiotherapy (CCRT) using the Etoposide–Cisplatin (EP) regimen in combination with intensity-modulated radiation therapy (IMRT) in patients with limited-stage small cell lung cancer (SCLC). Methods: A descriptive longitudinal study incorporating both retrospective and prospective data was conducted at K Hospital from June 2018 to June 2023 on 45 patients treated with the EP regimen and IMRT. Treatment outcomes were assessed using RECIST 1.1 criteria, overall response rate (ORR), progression-free survival (PFS), and adverse events categorized according to CTCAE version 4.0. Results: The overall response rate reached 91.1%, including 51.1% of patients achieving complete response. Recurrence or metastasis occurred in 73.3% of cases, and 42.2% of patients died during the follow-up period. The most common adverse events were leukopenia (73.3%), anorexia (62.2%), nausea/vomiting (48.9%), and radiation-induced dermatitis (39.9%). Severe side effects primarily affected the hematologic system, while non-hematologic and radiotherapy-related toxicities were generally well controlled. Conclusion: Concurrent chemoradiotherapy using the EP regimen and IMRT demonstrated high therapeutic efficacy with manageable toxicity in patients with limited-stage SCLC. These findings support the clinical application of this regimen in oncology practice in Vietnam